Off-label AMD therapies

Article

What are doctors using off-label to treat their AMD patients?

                                       

Avastin (Genentech): Anti-VEGF

Avastin (bevacizumab) is a recombitant humanized, full-length, anti-VEGF monoclonal antibody that binds all isoforms of VEGF-A. Although it is currently only approved for the treatment of colorectal and lung cancer, it is being widely used, off-label, for treatin wet AMD.

In May 2007, the Italian Pharmaceutical Agency (AIFA) announced the reimbursement of Avastin for the treatment of exudative maculopathy and neovascular glaucoma. As such, the agent, which has not been approved for this indication, would be fully reimbursed for use in Italian patients. Click here to read two experts opposing view of this decision.

The manufacturers of Avastin, Genentech, are now trying to prevent the drug being used off-label in the US by restricting sales to independent compounding pharmacies, which divide vials of the drug into smaller portions for use by ophthalmologists. This decision has caused uproar among US retina specialists.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.